SEC Form 4 · accession 0001104659-17-043883
Mersana Therapeutics, Inc. · MRSN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anna Protopapas
Officer — President and CEO · Director
Period of report
Jul 3, 2017
Accepted (ET)
Jul 6, 2017 · 5:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001442836
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 3, 2017 | C | 72,263 | — | A | 192,565 | I | By Kinney/Protopapas Family Irrevocable Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B-1 Convertible Preferred StockF2,F1 | — | Jul 3, 2017 | C | 325,189 | D | — | — | Common Stock | 72,263 | 0 | I |
Explanation of responses
- F1Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into .22222 shares of Common Stock without payment of further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock.
- F2These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.